Long-term effectiveness of intravitreal bevacizumab for choroidal neovascularization secondary to angioid streaks in pseudoxanthoma elasticum

Retina

Volumn 31, Issue 7, 2011, Pages 1268-1278

  Finger, Robert P ^a   Issa, Peter Charbel ^a,b   Schmitz Valckenberg, Steffen ^a   Holz, Frank G ^a   Scholl, Hendrik N ^a,c  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

angioid streaks; bevacizumab Avastin; choroidal neovascularization (CNV); fundus autofluorescence (FAF); pseudoxanthoma elasticum (PXE); retinal pigment epithelium (RPE)

Indexed keywords

BEVACIZUMAB;

ADULT; AGED; ANGIOID STREAK; ARTICLE; ATROPHY; CLINICAL ARTICLE; COHORT ANALYSIS; DRUG EFFECT; DRUG EFFICACY; FEMALE; FIBROSIS; FOLLOW UP; HUMAN; MALE; PIGMENT EPITHELIUM; PSEUDOXANTHOMA ELASTICUM; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; VISUAL ACUITY;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANGIOID STREAKS; ANTIBODIES, MONOCLONAL, HUMANIZED; ATROPHY; CHOROIDAL NEOVASCULARIZATION; COLORING AGENTS; FEMALE; FIBROSIS; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; INDOCYANINE GREEN; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; PSEUDOXANTHOMA ELASTICUM; RETINAL PIGMENT EPITHELIUM; RETREATMENT; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 79961207440     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e318207d1dc     Document Type: Article

References (31)

1. Hu X, Plomp AS, van Soest S, Wijnholds J, de Jong PT, Bergen AA. Pseudoxanthoma elasticum: a clinical, histopathological, and molecular update. Surv Ophthalmol 2003;48: 424-438. (Pubitemid 36798130)
2. Finger RP, Charbel Issa P, Ladewig MS, et al. Pseudoxanthoma elasticum: genetics, clinical manifestations and therapeutic approaches. Surv Ophthalmol 2009;54:272-285.
3. Chassaing N, Martin L, Calvas P, Le Bert M, Hovnanian A. Pseudoxanthoma elasticum: a clinical, pathophysiological and genetic update including 11 novel ABCC6 mutations. J Med Genet 2005;42:881-892. (Pubitemid 41811309)
4. Gass JD. "Comet" lesion: an ocular sign of pseudoxanthoma elasticum. Retina 2003;23:729-730. (Pubitemid 37315071)
5. Agarwal A, Patel P, Adkins T, Gass JD. Spectrum of pattern dystrophy in pseudoxanthoma elasticum. Arch Ophthalmol 2005;123:923-928. (Pubitemid 41057988)
6. Sawa M, Ober MD, Freund KB, Spaide RF. Fundus autofluorescence in patients with pseudoxanthoma elasticum. Ophthalmology 2006;113:814.e2-820.e2.
7. Charbel Issa P, Finger RP, Holz FG, Scholl HP. Multimodal imaging including spectral domain OCT and confocal near infrared reflectance for characterisation of outer retinal pathology in pseudoxanthoma elasticum. Invest Ophthalmol Vis Sci 2009;50:5913-5918.
8. Charbel Issa P, Finger RP, Goetting C, Hendig D, Holz FG, Scholl HP. Centrifugal fundus abnormalities in pseudoxanthoma elasticum. Ophthalmology 2010;117:1406-1414.
9. Ciulla TA, Rosenfeld PJ. Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than agerelated macular degeneration. Curr Opin Ophthalmol 2009; 20:166-174.
10. Finger RP, Charbel Issa P, Ladewig M, Holz FG, Scholl HP. Intravitreal bevacizumab for choroidal neovascularisation associated with pseudoxanthoma elasticum. Br J Ophthalmol 2008;92:483-487. (Pubitemid 351497973)
11. Pedersen R, Soliman W, Lund-Andersen H, Larsen M. Treatment of choroidal neovascularization using intravitreal bevacizumab. Acta Ophthalmol Scand 2007;85:526-533. (Pubitemid 47163114)
12. Teixeira A, Moraes N, Farah ME, Bonomo PP. Choroidal neovascularization treated with intravitreal injection of bevacizumab (Avastin) in angioid streaks. Acta Ophthalmol Scand 2006;84:835-836. (Pubitemid 44688345)
13. Deutsche Ophthalologische Gesellschaft, Retinologische Gesellschaft, Deutschlands BdA. Neue Aspekte in der Therapie der neovaskulären altersabhängigen Makuladegeneration [New Aspects in the Therapy of Age-Related Macular Degeneration]. American Academy of Ophthalmology Retina Panel. Preferred Practice Pattern Guidelines. Age-Related Macular Degeneration. San Francisco, CA: America Academy of Ophthalmology; 2008. Available at: .
14. Mitchell P, Korobelnik JF, Lanzetta P, et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol 2010;94:2-13.
15. Finger RP, Charbel Issa P, Ladewig M, Gotting C, Holz FG, Scholl HP. Fundus autofluorescence in pseudoxanthoma elasticum. Retina 2009;29:1496-1505.
16. Schmitz-Valckenberg S, Jorzik J, Unnebrink K, Holz FG. Analysis of digital scanning laser ophthalmoscopy fundus autofluorescence images of geographic atrophy in advanced age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2002;240:73-78. (Pubitemid 36075577)
17. Deckert A, Schmitz-Valckenberg S, Jorzik J, Bindewald A, Holz FG, Mansmann U. Automated analysis of digital fundus autofluorescence images of geographic atrophy in advanced age-related macular degeneration using confocal scanning laser ophthalmoscopy (cSLO). BMC Ophthalmol 2005;5:8.
18. Kang S, Roh YJ. Intravitreal ranibizumab for choroidal neovascularisation secondary to angioid streaks. Eye 2009; 23:1750-1751.
19. Sen PR, Rishi P, Sen P, Rishi E, Shroff D. Rapid progression of angioid streaks following intravitreal bevacizumab. Can J Ophthalmol 2009;44:e39-e40.
20. Donati MC, Virgili G, Bini A, et al. Intravitreal bevacizumab (Avastin) for choroidal neovascularization in angioid streaks: a case series. Ophthalmologica 2009;223:24-27.
21. Kovach JL, Schwartz SG, Hickey M, Puliafito CA. Thirty-two month follow-up of successful treatment of choroidal neovascularization from angioid streaks with intravitreal bevacizumab. Ophthalmic Surg Lasers Imaging 2009;40:77-79.
22. Molina Guilabert I, Calvo-Gonzalez C, Reche-Frutos J, et al. Intravitreal pegabtanib sodium in choroidal neovascularization secondary to angioid streaks. Acta Ophthalmol 2009;87: 581-582.
23. Schiano Lomoriello D, Parravano MC, Chiaravalloti A, Varano M. Choroidal neovascularization in angioid streaks and pseudoxanthoma elasticum: 1 year follow-up. Eur J Ophthalmol 2009; 19:151-153.
24. Wiegand TW, Rogers AH, McCabe F, Reichel E, Duker JS. Intravitreal bevacizumab (Avastin) treatment of choroidal neovascularisation in patients with angioid streaks. Br J Ophthalmol 2009;93:47-51.
25. Lommatzsch A, Spital G, Trieschmann M, Pauleikhoff D. [Intraocular application of bevacizumab for the treatment of choroidal neovascularization secondary to angioid streaks.] Ophthalmologe 2007;104:325-328.
26. Sawa M, Gomi F, Tsujikawa M, Sakaguchi H, Tano Y. Longterm results of intravitreal bevacizumab injection for choroidal neovascularization secondary to angioid streaks. Am J Ophthalmol 2009;148:584.e2-590.e2.
27. Neri P, Salvolini S, Mariotti C, Mercanti L, Celani S, Giovannini A. Long-term control of choroidal neovascularisation secondary to angioid streaks treated with intravitreal bevacizumab (Avastin). Br J Ophthalmol 2009;93:155-158.
28. Wong TY, Liew G, Mitchell P. Clinical update: new treatments for age-relatedmacular degeneration. Lancet 2007;370:204-206. (Pubitemid 47069522)
29. Gibran SK, Sachdev A, Stappler T, Newsome R, Wong D, Hiscott P. Histological findings of a choroidal neovascular membrane removed at the time of macular translocation in a patient previously treated with intravitreal bevacizumab treatment (Avastin). Br J Ophthalmol 2007;91:602-604. (Pubitemid 46716525)
30. Shimomura Y, Hirata A, Ishikawa S, Okinami S. Changes in choriocapillaris fenestration of rat eyes after intravitreal bevacizumab injection. Graefes Arch Clin Exp Ophthalmol 2009;247:1089-1094.
31. Klettner AK, Kruse ML, Meyer T, Wesch D, Kabelitz D, Roider J. Different properties of VEGF-antagonists: bevacizumab but not ranibizumab accumulates in RPE cells. Graefes Arch Clin Exp Ophthalmol 2009;247:1601-1608.